title: MEK and the inhibitors: from bench to bedside.
abstract: Four distinct MAP kinase signaling pathways involving 7 MEK enzymes have been identified. MEK1 and MEK2 are the prototype members of MEK family proteins. Several MEK inhibitors are in clinical trials. Trametinib is being evaluated by FDA for the treatment of metastatic melanoma with BRAF V600 mutation. Selumetinib has been studied in combination with docetaxel in phase II randomized trial in previously treated patients with advanced lung cancer. Selumetinib group had better response rate and progression-free survival. This review also summarized new MEK inhibitors in clinical development, including pimasertib, refametinib, PD-0325901, TAK733, MEK162 (ARRY 438162), RO5126766, WX-554, RO4987655 (CH4987655), GDC-0973 (XL518), and AZD8330.
authors.affiliation: Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY 10595, USA. DELONG_LIU@NYMC.EDU.
authors.forename: Akintunde
authors.initials: A
authors.lastname: Akinleye
authors.forename: Muhammad
authors.initials: M
authors.lastname: Furqan
authors.forename: Nikhil
authors.initials: N
authors.lastname: Mukhi
authors.forename: Pavan
authors.initials: P
authors.lastname: Ravella
authors.forename: Delong
authors.initials: D
authors.lastname: Liu
mesh_terms: D006801:Humans; D048369:MAP Kinase Kinase 1 / Q000037:antagonists & inhibitors*; D009369:Neoplasms / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*
chemical_list: D047428:Protein Kinase Inhibitors; D048369:MAP Kinase Kinase 1